Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rexahn Pharmaceuticals Inc (NYSE MKT LLC:RNN)

0.56
Delayed Data
As of 1:40pm ET
 0.00 / 0.00%
Today’s Change
0.50
Today|||52-Week Range
0.96
-20.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$101.2M

Company Description

Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The company currently has three clinical stage oncology candidates, Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Contact Information

Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Rockville Maryland 20850
P:(240) 268-5300
Investor Relations:

Employees

Shareholders

Mutual fund holders3.39%
Individual stakeholders10.59%
Other institutional1.53%

Top Executives

Peter David SuzdakChief Executive Officer & Director
Tae Heum JeongChief Financial Officer & Secretary
Chang Ho AhnChairman-Emeritus & Chief Scientist
Ely BenaimChief Medical Officer